Coiante Scott M
Known title: SVP, Chief Financial OfficerCIK: 0001608536
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Aprea Therapeutics Announces October Conference Presentations. Aprea Therapeutics will present at several conferences in October. The company’s appearance is intended to share progress on its research and development efforts. The presentation may offer new information to investors and analysts about the company’s pipeline and strategy. The event is a routine update for the company’s stakeholders.
Transaction History
| LXRX | ▲ Buy | Option Exercise | 160,237 | — | 2/28/2026 | View on chart |
| LXRX | ▼ Sell | Tax Withholding | 54,881 | $81K | 2/28/2026 | View on chart |
| APRE | ▲ Buy | Grant | 60,800 | $0 | 7/28/2022 | View on chart |
| APRE | ▼ Sell | Tax Withholding | 35,284 | $28K | 6/3/2022 | View on chart |
| APRE | ▲ Buy | Grant | 42,900 | $0 | 3/10/2022 | View on chart |
| APRE | ▼ Sell | Tax Withholding | 14,817 | $26K | 2/25/2022 | View on chart |
| APRE | ▼ Sell | Tax Withholding | 7,534 | $30K | 8/25/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Lexicon Reports Consistent Heart Failure Drug Data in New Analysis
Lexicon Pharmaceuticals announced new analysis from the SOLOIST-WHF trial showing its drug sotagliflozin produced consistent results in patients with worsening heart failure across different baseline blood pressure levels. This post hoc analysis reinforces findings from the original trial studying hospitalized heart failure patients. The company also confirmed participation in three upcoming investor conferences, a routine corporate engagement practice. The data announcement represents the substantive news for this period.
Lexicon Reports Consistent Heart Failure Drug Data in New Analysis. Lexicon Pharmaceuticals announced new analysis from the SOLOIST-WHF trial showing its drug sotagliflozin produced consistent results in patients with worsening heart failure across different baseline blood pressure levels. This post hoc analysis reinforces findings from the original trial studying hospitalized heart failure patients. The company also confirmed participation in three upcoming investor conferences, a routine corporate engagement practice. The data announcement represents the substantive news for this period.